The possible split of Doliprane into an American fund raises concerns about the risks of relocation of its production and the availability of the drug in France.
:quality(50)/2023/07/07/64a7df4c5fe71_placeholder-36b69ec8.png)
Published
Reading time: 1 min
:quality(50)/2024/10/11/doliprane2-6709411ba1b4c260510556.jpg)
“In the next five or six years, there is no risk” shortage of Doliprane in France, estimated Friday October 11 on franceinfo Bruno Bonnemain, president of the National Academy of Pharmacy, regarding the potential takeover of Doliprane by the United States, after the announcement of ongoing negotiations between Sanofi and an American investment fund.
The French pharmaceutical group has confirmed that it is in exclusive negotiations with the American fund CD&R to sell it a majority stake in Opella, an entity which markets the very popular paracetamol brand Doliprane.
“It’s obvious that this goes against the policy that France and Europe seek to pursue” on health sovereignty, Bruno Bonnemain first reacted. “I think that in the next five or six years, there is no risk.” shortage in France, “but it’s after that that it could pose a problem”.
“The problem is that when the decision-making centers are no longer in Europe, anything can happencontinued the pharmacist. This is the problem we have, for example, with China and India who can suddenly decide to no longer supply Europe as a priority. We can imagine in the long term that it will be the same thing with the United States.”
“Many large pharmaceutical companies have decided to focus on innovative and expensive products and sell their less profitable and older productsalso analyzes Bruno Bonnemain. It’s a fairly general movement.”.